6BG Stock Chart & Stats
€0.61
>-€0.01(-1.25%)
At close: 4:00 PM EST
€0.61
>-€0.01(-1.25%)
Day’s Range― - ―
52-Week Range€0.57 - €1.02
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€62.78M
Enterprise Value€604.27
Total Cash (Recent Filing)€117.90M
Total Debt (Recent Filing)€2.88M
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.67
Shares Outstanding76,900,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lytix Biopharma AS News
6BG FAQ
What was Lytix Biopharma AS’s price range in the past 12 months?
Lytix Biopharma AS lowest stock price was €0.57 and its highest was €1.01 in the past 12 months.
What is Lytix Biopharma AS’s market cap?
Lytix Biopharma AS’s market cap is €62.78M.
When is Lytix Biopharma AS’s upcoming earnings report date?
Lytix Biopharma AS’s upcoming earnings report date is Aug 27, 2026 which is in 29 days.
How were Lytix Biopharma AS’s earnings last quarter?
Lytix Biopharma AS released its earnings results on May 21, 2026. The company reported -€0.031 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Lytix Biopharma AS overvalued?
According to Wall Street analysts Lytix Biopharma AS’s price is currently Overvalued.
Does Lytix Biopharma AS pay dividends?
Lytix Biopharma AS does not currently pay dividends.
What is Lytix Biopharma AS’s EPS estimate?
Lytix Biopharma AS’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lytix Biopharma AS have?
Lytix Biopharma AS has 76,900,000 shares outstanding.
What happened to Lytix Biopharma AS’s price movement after its last earnings report?
Lytix Biopharma AS reported an EPS of -€0.031 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.381%.
Which hedge fund is a major shareholder of Lytix Biopharma AS?
Currently, no hedge funds are holding shares in DE:6BG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lytix Biopharma AS
Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology firm dedicated to advancing innovative immunotherapies for cancer treatment. Its primary drug candidate, LTX-315, is an oncolytic molecule currently undergoing Phase II clinical trials. This therapy is formulated for intratumoral injection, aiming to provide localized treatment for solid tumors. Additionally, Lytix Biopharma is developing LTX-401, another oncolytic molecule in its preclinical phase, specifically designed to target deep-seated cancerous lesions, including those found in liver cancer. The company was established in 2003.